prochlorperazine gh
generic health pty ltd - prochlorperazine maleate -
prochlorperazine-ga
actavis pty ltd - prochlorperazine maleate -
prochlorperazine-ps
scentia pharmaceuticals pty ltd - prochlorperazine maleate -
solian
sanofi-aventis australia pty ltd - amisulpride -
stemetil
sanofi-aventis australia pty ltd - prochlorperazine maleate; prochlorperazine mesylate -
sulprix
alphapharm pty ltd - amisulpride -
stemetil prochlorperazine maleate 25mg suppositories blister pack
sanofi-aventis australia pty ltd - prochlorperazine maleate -
antinaus
viatris limited - prochlorperazine maleate 5mg; prochlorperazine maleate 5mg - tablet - 5 mg - active: prochlorperazine maleate 5mg excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone active: prochlorperazine maleate 5mg excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone - antinaus is used in vertigo due to meniere's syndrome, labyrinthitis and other causes, and for nausea and vomiting from whatever cause. it may also be used for migraine, schizophrenia (particularly in the chronic stage), acute mania and as an adjunct to the short term management of anxiety.
antinaus
viatris limited - prochlorperazine maleate 5mg; prochlorperazine maleate 5mg - tablet - 5 mg - active: prochlorperazine maleate 5mg excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone active: prochlorperazine maleate 5mg excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone - for the treatement of nausea associated with migrane.
solian
sanofi-aventis new zealand limited - amisulpride 100 mg/ml; - oral solution - 100 mg/ml - active: amisulpride 100 mg/ml excipient: caramel hydrochloric acid methyl hydroxybenzoate potassium sorbate propyl hydroxybenzoate purified water sweetener gesweet 01002023 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.